Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00050098.xml
Download PDF
CC BY-NC-ND 4.0 · Journal of Coloproctology 2023; 43(02): 139-151
DOI: 10.1055/s-0043-1769919
DOI: 10.1055/s-0043-1769919
Review Article
Possible Therapeutics for Pseudomyxoma Peritonei: A Rare, Lethal, and the Least Investigated Disease
Abstract
Pseudomyxoma peritonei (PMP) refers to a growth disorder characterized by glycoprotein neoplasm in the peritoneum, where mucin oversecretion occurs. The tumors of the appendix region are well associated with PMP; however, ovarian, colon, stomach, pancreas, and urachus tumors have also been linked to PMP. Other mucinous tumors in the pelvis, paracolic gutters, greater omentum, retrohepatic space, and Treitz ligament can be the reason for PMP. Despite being rare and having a slow growth rate, PMP can be lethal without treatment. It is treated with neoadjuvant chemotherapy with the option of cytoreductive surgery and intraperitoneal chemotherapy. In the current study, we hypothesize that there may be novel gentle ways to inhibit or eliminate the mucin. Dr. David Morris has used mucolytics—such as bromelain and N-acetyl cysteine to solubilize mucin. In the present review, we aimed to study the regulation of mucin expression by promoter methylation, and drugs that can inhibit mucin, such as boldine, amiloride, naltrexone, dexamethasone, and retinoid acid receptors antagonist. This review also explored some possible pathways, such as inhibition of Na + , Ca2+ channels and induction of DNA methyltransferase along with inhibition of ten-eleven translocation enzymes, which can be good targets to control mucin. Mucins are strong adhesive molecules that play great roles in clinging to cells or cell to cell. Besides, they have been greatly involved in metastasis and also act as disease markers for cancers. Diagnostic markers may have exclusive roles in disease initiation and progression. Therefore, the present review explores various drugs to control and target mucin in various diseases, specifically cancers.
Publication History
Received: 17 December 2022
Accepted: 07 March 2023
Article published online:
23 June 2023
© 2023. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Ang CS-P, Shen JP, Hardy-Abeloos CJ. et al. Genomic landscape of appendiceal neoplasms. JCO Precis Oncol 2018; 2: 1-18
- 2 Vlaeminck-Guillem V, Bienvenu J, Isaac S. et al. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies). Ann Surg Oncol 2013; 20 (08) 2655-2662
- 3 Leonards LM, Pahwa A, Patel MK, Petersen J, Nguyen MJ, Jude CM. Neoplasms of the appendix: pictorial review with clinical and pathologic correlation. Radiographics 2017; 37 (04) 1059-1083
- 4 Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994; 219 (02) 109-111
- 5 Rosenberger LH, Stein LH, Witkiewicz AK, Kennedy EP, Yeo CJ. Intraductal papillary mucinous neoplasm (IPMN) with extra-pancreatic mucin: a case series and review of the literature. J Gastrointest Surg 2012; 16 (04) 762-770
- 6 Agrawal AK, Bobiński P, Grzebieniak Z. et al. Pseudomyxoma peritonei originating from urachus-case report and review of the literature. Curr Oncol 2014; 21 (01) e155-e165
- 7 Vang R, Gown AM, Zhao C. et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 2007; 31 (06) 854-869
- 8 Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4 (01) 45-60
- 9 Tan GHC, Novo CA, Dayal S. et al. The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin. Eur J Surg Oncol 2017; 43 (02) 388-394
- 10 Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta 2014; 1846 (01) 142-151
- 11 de Lima NMR, Ferreira EO, Fernandes MY. et al. Neuroinflammatory response to experimental stroke is inhibited by boldine. Behav Pharmacol 2017; 28 (2 and 3-Spec Issue): 223-237
- 12 Resendiz-Albor AA, Arciniega-Martinez IM, Santamaria-Chavez MM, Rebollar-Ruiz XA, Campos-Rodriguez R. Effect of Muscarine and Atropine on the production of myeloperoxidase and proinflammatory cytokines in small intestine. J Immunol 2019
- 13 Walstab J, Wohlfarth C, Hovius R. et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil 2014; 26 (06) 810-820
- 14 Utsumi D, Matsumoto K, Amagase K, Horie S, Kato S. 5-HT3 receptors promote colonic inflammation via activation of substance P/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis. Br J Pharmacol 2016; 173 (11) 1835-1849
- 15 Lau Y-S, Machha A, Achike FI, Murugan D, Mustafa MR. The aporphine alkaloid boldine improves endothelial function in spontaneously hypertensive rats. Exp Biol Med (Maywood) 2012; 237 (01) 93-98
- 16 Moreno PRH, Vargas VMF, Andrade HHR, Henriques AT, Henriques JAP. Genotoxicity of the boldine aporphine alkaloid in prokaryotic and eukaryotic organisms. Mutat Res 1991; 260 (02) 145-152
- 17 Jiménez I, Garrido A, Bannach R, Gotteland M, Speisky H. Protective effects of boldine against free radical-induced erythrocyte lysis. Phytother Res 2000; 14 (05) 339-343
- 18 Pandurangan AK, Mohebali N, Hasanpourghadi M, Looi CY, Mustafa MR, Mohd Esa N. Boldine suppresses dextran sulfate sodium-induced mouse experimental colitis: NF-κB and IL-6/STAT3 as potential targets. Biofactors 2016; 42 (03) 247-258
- 19 Fernández J, Lagos P, Rivera P, Zamorano-Ponce E. Effect of boldo (Peumus boldus Molina) infusion on lipoperoxidation induced by cisplatin in mice liver. Phytother Res 2009; 23 (07) 1024-1027
- 20 Yu S-M, Lee S-S, Hou Y-S, Teng C-M. Mechanisms of vasorelaxation induced by N-allylsecoboldine in rat thoracic aorta. Naunyn Schmiedebergs Arch Pharmacol 1994; 349 (06) 637-643
- 21 Subramaniam N, Kannan P, K A, Thiruvengadam D. Hepatoprotective effect of boldine against diethylnitrosamine-induced hepatocarcinogenesis in wistar rats. J Biochem Mol Toxicol 2019; 33 (12) e22404
- 22 Yu B, Cook C, Santanam N. The aporphine alkaloid boldine induces adiponectin expression and regulation in 3T3-L1 cells. J Med Food 2009; 12 (05) 1074-1083
- 23 Tomšík P, Mičuda S, Muthná D. et al. Boldine inhibits mouse mammary carcinoma in vivo and human MCF-7 breast cancer cells in vitro. Planta Med 2016; 82 (16) 1416-1424
- 24 Paydar M, Kamalidehghan B, Wong YL, Wong WF, Looi CY, Mustafa MR. Evaluation of cytotoxic and chemotherapeutic properties of boldine in breast cancer using in vitro and in vivo models. Drug Des Devel Ther 2014; 8: 719-733
- 25 Gerhardt D, Bertola G, Dietrich F. et al. Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3β. Urol Oncol 2014; 32 (01) 36.e1-36.e9
- 26 Gerhardt D, Horn AP, Gaelzer MM. et al. Boldine: a potential new antiproliferative drug against glioma cell lines. Invest New Drugs 2009; 27 (06) 517-525
- 27 Zhou Z, Treis D, Schubert SC. et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 2008; 178 (12) 1245-1256
- 28 Xu H, Li Q, Zhao Y, Li J, Ghishan FK. Intestinal NHE8 is highly expressed in goblet cells and its expression is subject to TNF-α regulation. Am J Physiol Gastrointest Liver Physiol 2016; 310 (02) G64-G69
- 29 Soleiman AA, Thameem F, Khan I. Mechanism of down regulation of Na-H exchanger-2 in experimental colitis. PLoS One 2017; 12 (05) e0176767
- 30 Cantero-Recasens G, Butnaru CM, Brouwers N, Mitrovic S, Valverde MA, Malhotra V. Sodium channel TRPM4 and sodium/calcium exchangers (NCX) cooperate in the control of Ca2+-induced mucin secretion from goblet cells. J Biol Chem 2019; 294 (03) 816-826
- 31 Mitrovic S, Nogueira C, Cantero-Recasens G. et al. TRPM5-mediated calcium uptake regulates mucin secretion from human colon goblet cells. eLife 2013; 2: e00658
- 32 Friedman PA, Gesek FA. Cellular calcium transport in renal epithelia: measurement, mechanisms, and regulation. Physiol Rev 1995; 75 (03) 429-471
- 33 Nilius B, Prenen J, Droogmans G. et al. Voltage dependence of the Ca2+-activated cation channel TRPM4. J Biol Chem 2003; 278 (33) 30813-30820
- 34 Hofmann T, Chubanov V, Gudermann T, Montell C. TRPM5 is a voltage-modulated and Ca(2+)-activated monovalent selective cation channel. Curr Biol 2003; 13 (13) 1153-1158
- 35 Launay P, Fleig A, Perraud AL, Scharenberg AM, Penner R, Kinet JP. TRPM4 is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization. Cell 2002; 109 (03) 397-407
- 36 Liu D, Liman ER. Intracellular Ca2+ and the phospholipid PIP2 regulate the taste transduction ion channel TRPM5. Proc Natl Acad Sci U S A 2003; 100 (25) 15160-15165
- 37 Coombes S, Hinch R, Timofeeva Y. Receptors, sparks and waves in a fire-diffuse-fire framework for calcium release. Prog Biophys Mol Biol 2004; 85 (2-3): 197-216
- 38 Dupont G, Combettes L, Bird GS, Putney JW. Calcium oscillations. Cold Spring Harb Perspect Biol 2011; 3 (03) a004226
- 39 Putney JW, Tomita T. Phospholipase C signaling and calcium influx. Adv Biol Regul 2012; 52 (01) 152-164
- 40 Adler KB, Tuvim MJ, Dickey BF. Regulated mucin secretion from airway epithelial cells. Front Endocrinol (Lausanne) 2013; 4: 1-9
- 41 Carrión AM, Link WA, Ledo F, Mellström B, Naranjo JR. DREAM is a Ca2+-regulated transcriptional repressor. Nature 1999; 398 (6722): 80-84
- 42 Grillo MA, Grillo SL, Gerdes BC, Kraus JG, Koulen P. Control of neuronal ryanodine receptor-mediated calcium signaling by calsenilin. Mol Neurobiol 2019; 56 (01) 525-534
- 43 Lilliehook C, Chan S, Choi EK. et al. Calsenilin enhances apoptosis by altering endoplasmic reticulum calcium signaling. Mol Cell Neurosci 2002; 19 (04) 552-559
- 44 Choudry HA, Mavanur A, O'Malley ME, Zeh HJ, Guo Z, Bartlett DL. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol 2012; 19 (05) 1402-1409
- 45 Van Seuningen I, Pigny P, Perrais M, Porchet N, Aubert J-P. Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer?. Front Biosci 2001; 6: D1216-D1234
- 46 Vincent A, Perrais M, Desseyn JL, Aubert JP, Pigny P, Van Seuningen I. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 2007; 26 (45) 6566-6576
- 47 Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004; 1680 (02) 114-128
- 48 Kai H, Yoshitake K, Hisatsune A. et al. Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am J Physiol 1996; 271 (3 Pt 1): L484-L488
- 49 Yuan S, Hollinger M, Lachowicz-Scroggins ME. et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci Transl Med 2015; 7 (276) 276ra27
- 50 Demouveaux B, Gouyer V, Robbe-Masselot C, Gottrand F, Narita T, Desseyn JL. Mucin CYS domain stiffens the mucus gel hindering bacteria and spermatozoa. Scientific reports 2019; 9 (01) 16993
- 51 Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Medical sciences (Basel, Switzerland) 2018; 6 (04) 82
- 52 Meng J, Meng Y, Plotnikoff NP, Youkilis G, Griffin N, Shan F. Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs). Int Immunopharmacol 2013; 17 (04) 1084-1089
- 53 Yi Z, Guo S, Hu X. et al. Functional modulation on macrophage by low dose naltrexone (LDN). Int Immunopharmacol 2016; 39: 397-402
- 54 Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol 2011; 122 (02) 382-388
- 55 Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 2014; 33 (04) 451-459
- 56 Chopra P, Cooper MS. Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol 2013; 8 (03) 470-476
- 57 Good P. Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?. Med Hypotheses 2006; 67 (03) 671-672
- 58 San-Emeterio EP, Hurlé MA. Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice. Neurosci Lett 2006; 403 (03) 276-279
- 59 Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol 2014; 20 (09) 2218-2223
- 60 Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous α-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther 2006; 5 (01) 83-89
- 61 Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (α-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 2009; 8 (04) 416-422
- 62 Ebrahimpour S, Tabari MA, Youssefi MR, Aghajanzadeh H, Behzadi MY. Synergistic effect of aged garlic extract and naltrexone on improving immune responses to experimentally induced fibrosarcoma tumor in BALB/c mice. Pharmacognosy Res 2013; 5 (03) 189-194
- 63 Khan A. Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3–a case report. Oral Health Dent Manag 2014; 13 (03) 721-724
- 64 Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol 2018; 61: 178-184
- 65 Amin D, El Teliti A. Evaluation of the protective effect of low dose naltrexone against 2, 4 toluene diisocyanate induced toxicity in albino rats. Zagazig J Forensic Med 2017; 15: 18-28
- 66 Tawfik DI, Osman AS, Tolba HM, Khattab A, Abdel-Salam LO, Kamel MM. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats. Neuropeptides 2016; 59: 39-45
- 67 Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2018; 4 (04) CD010410
- 68 Lie MRKL, van der Giessen J, Fuhler GM, de Lima A, Peppelenbosch MP, van der Ent C, van der Woude CJ. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. Journal of translational medicine 2018; 16 (01) 55
- 69 Issa J-PJ. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007; 13 (06) 1634-1637
- 70 Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013; 502 (7472): 472-479
- 71 Williams K, Christensen J, Pedersen MT. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011; 473 (7347): 343-348
- 72 Huff-Hardy K, Kwon JH. Hydroxymethylation Influences on Intestinal Epithelial Cells in Health and Disease in Gene Expression and Regulation in Mammalian Cells-Transcription Toward the Establishment of Novel Therapeutics. IntechOpen; 2018
- 73 Scourzic L, Mouly E, Bernard OA. TET proteins and the control of cytosine demethylation in cancer. Genome medicine 2015; 7 (01) 9
- 74 Chua GNL, Wassarman KL, Sun H. et al. Cytosine-based TET enzyme inhibitors. ACS Med Chem Lett 2019; 10 (02) 180-185
- 75 Bollag W, Isnardi L, Jablonska S. et al. Links between pharmacological properties of retinoids and nuclear retinoid receptors. Int J Cancer 1997; 70 (04) 470-472
- 76 Eyrolles L, Kagechika H, Kawachi E. et al. Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring. J Med Chem 1994; 37 (10) 1508-1517
- 77 Thornton DJ, Howard M, Khan N, Sheehan JK. Identification of two glycoforms of the MUC5B mucin in human respiratory mucus. Evidence for a cysteine-rich sequence repeated within the molecule. J Biol Chem 1997; 272 (14) 9561-9566
- 78 Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8 (08) 1333-1338
- 79 Kim KC, Jeffery PK. Airway mucus. Eur Respir J 1997; 10 (07) 1438-1438
- 80 Steiger D, Hotchkiss J, Bajaj L, Harkema J, Basbaum C. Concurrent increases in the storage and release of mucin-like molecules by rat airway epithelial cells in response to bacterial endotoxin. Am J Respir Cell Mol Biol 1995; 12 (03) 307-314
- 81 An G, Luo G, Wu R. Expression of MUC2 gene is down-regulated by vitamin A at the transcriptional level in vitro in tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 1994; 10 (05) 546-551
- 82 Guzman K, Gray TE, Yoon JH, Nettesheim P. Quantitation of mucin RNA by PCR reveals induction of both MUC2 and MUC5AC mRNA levels by retinoids. Am J Physiol 1996; 271 (6 Pt 1): L1023-L1028
- 83 Gray TE, Guzman K, Davis CW, Abdullah LH, Nettesheim P. Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 1996; 14 (01) 104-112
- 84 Alam J, de Paiva CS, Pflugfelder SC. Immune - Goblet cell interaction in the conjunctiva. Ocul Surf 2020; 18 (02) 326-334
- 85 Xiao Y, de Paiva CS, Yu Z, de Souza RG, Li DQ, Pflugfelder SC. Goblet cell-produced retinoic acid suppresses CD86 expression and IL-12 production in bone marrow-derived cells. Int Immunol 2018; 30 (10) 457-470
- 86 Jijon HB, Suarez-Lopez L, Diaz OE. et al. Intestinal epithelial cell-specific RARα depletion results in aberrant epithelial cell homeostasis and underdeveloped immune system. Mucosal Immunol 2018; 11 (03) 703-715
- 87 Rogers DF, Barnes PJ, Alton EW, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006; 38 (02) 116-125
- 88 Christensen TG, Breuer R, Haddad CE, Niles RM. Quantitative ultrastructural analysis of the relationship between cell growth, shape change, and mucosecretory differentiation in cultured hamster tracheal epithelial cells exposed to retinoic acid. Am J Respir Cell Mol Biol 1993; 9 (03) 287-294
- 89 Obinata A, Osakabe K, Yamaguchi M, Morimoto R, Akimoto Y. Tgm2/Gh, Gbx1 and TGF-β are involved in retinoic acid-induced transdifferentiation from epidermis to mucosal epithelium. Int J Dev Biol 2011; 55 (10-12): 933-943
- 90 Wei PC, Tong L, Li R. [Effect of RORC inhibitor on HIF-1α and VEGF in nasal mucosa of allergic rhinitis of mice]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018; 53 (10) 751-756
- 91 Fujii U, Miyahara N, Taniguchi A, Oda N, Morichika D, Murakami E, Nakayama H, Waseda K, Kataoka M, Kakuta H, Tanimoto M, Kanehiro A. Effect of a retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness in a murine model of asthma. Respiratory research 2017; 18 (01) 23
- 92 Kandasamy J, Huda S, Ambalavanan N, Jilling T. Inflammatory signals that regulate intestinal epithelial renewal, differentiation, migration and cell death: Implications for necrotizing enterocolitis. Pathophysiology 2014; 21 (01) 67-80
- 93 VanDussen KL, Samuelson LC. Mouse atonal homolog 1 directs intestinal progenitors to secretory cell rather than absorptive cell fate. Dev Biol 2010; 346 (02) 215-223
- 94 Mulvaney J, Dabdoub A. Atoh1, an essential transcription factor in neurogenesis and intestinal and inner ear development: function, regulation, and context dependency. J Assoc Res Otolaryngol 2012; 13 (03) 281-293
- 95 Tasseff R, Jensen HA, Congleton J, Dai D, Rogers KV, Sagar A, Bunaciu RP, Yen A, Varner JD. An Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program. Scientific reports 2017; 7 (01) 14327
- 96 Dhingra D, Soni K. Behavioral and biochemical evidences for nootropic activity of boldine in young and aged mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 97: 895-904